1-15 of 444
Obesity and Asthma: Intersecting Pathways and Real-World Impacts
Clinician's RoundtableObesity and Asthma: Intersecting Pathways and Real-World Impacts
MASLD and MASH in Focus: Clinical Priorities and Promising Pathways
Clinician's RoundtableMASLD and MASH in Focus: Clinical Priorities and Promising Pathways
The Metabolic Roots of Early-Onset Colorectal Cancer
Project Oncology®The Metabolic Roots of Early-Onset Colorectal Cancer
MASLD Explained: A Modern Framework for a Multisystem Condition
Clinician's RoundtableMASLD Explained: A Modern Framework for a Multisystem Condition
Unveiling the Role of Obesity in MASLD Progression
Clinician's RoundtableUnveiling the Role of Obesity in MASLD Progression
New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Clinician's RoundtableNew Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
- advertisement
From Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Clinician's RoundtableFrom Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Assessing the Role of Metabolic Factors in Psoriasis Management
AudioAbstractsAssessing the Role of Metabolic Factors in Psoriasis Management
Finerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Heart MattersFinerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- advertisement
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
AIP Emerges as a Potential Marker for Diabetic Kidney Risk
Clinician's RoundtableAIP Emerges as a Potential Marker for Diabetic Kidney Risk
Pediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
On the Frontlines of PsoriasisPediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
